Abstract Number: 1059 • 2019 ACR/ARP Annual Meeting
BDCA2 Targeting of Human Plasmacytoid Dendritic Cells via CBS004 Reverts Dependent IFN Activation and Tissue Fibrosis in vitro and in vivo
Background/Purpose: Human plasmacytoid dendritic cells (pDCs) have been implicated in the pathogenesis of Systemic Sclerosis (SSc) through their ability to infiltrate the skin and secrete…Abstract Number: 1060 • 2019 ACR/ARP Annual Meeting
The Diversity and Community Metrics of the Esophageal Microbiome of SSc Patients
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by fibrosis and inflammation. Multiple organ systems are affected including the skin, gastrointestinal tract, vasculature, and…Abstract Number: 1061 • 2019 ACR/ARP Annual Meeting
PI3K-Akt Pathway Plays a Crucial Role in Production of Collagen in Fli1 Deficient Condition and Its Inhibitor Has the Therapeutic Potential in Treating Fibrosis
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by fibrosis of the skin and internal organs. Previous studies have shown that dermal fibroblast…Abstract Number: 1062 • 2019 ACR/ARP Annual Meeting
Lymphocyte Subset Abnormalities in Early Diffuse Cutaneous Systemic Sclerosis
Background/Purpose: A variety of abnormalities in lymphocyte surface markers and functional subsets have been described in patients with systemic sclerosis (SSc), but conflicting results abound,…Abstract Number: 1063 • 2019 ACR/ARP Annual Meeting
Effects of Abatacept on T Regulatory Cells in Early Diffuse Systemic Sclerosis
Background/Purpose: Background: In a randomized controlled trial of abatacept in early diffuse systemic sclerosis (Khanna D, et al ACR 2018), we observed early clinical flares…Abstract Number: 1064 • 2019 ACR/ARP Annual Meeting
CD123+ Plasmacytoid Dendritic Cells from Systemic Sclerosis Patients Are Susceptible to the Cytotoxic Activity of Tagraxofusp, a CD123-Targeted Therapy
Background/Purpose: Tagraxofusp is a novel targeted therapy directed to the interleukin-3 receptor (CD123). Tagraxofusp is comprised of human IL-3 recombinantly fused to a truncated diphtheria…Abstract Number: 1065 • 2019 ACR/ARP Annual Meeting
Aberrant Expression Levels of Soluble Co-inhibitory Receptors Linked to Disease Activity in Systemic Sclerosis
Background/Purpose: Emerging evidence suggests dysregulated T cell activation in systemic sclerosis (SSc). Co-inhibitory-receptors such as TIM-3, PD-1 and LAG-3 are key factors in immune homeostasis…Abstract Number: 1066 • 2019 ACR/ARP Annual Meeting
Dysregulated IL-6 Dependent Dermal Adenosine Signaling via Adenosine A2A Receptor May Drive Fibrosis in Systemic Sclerosis
Background/Purpose: Altered generation of adenosine from extracellular nucleotides by ectonucleotidases may orchestrate chronic injury responses and promote fibrosis via the adenosine A2A receptor (ADORA2A). We…Abstract Number: 1067 • 2019 ACR/ARP Annual Meeting
Identification of miRNAs in Systemic Sclerosis Based on Activity and Network Analysis
Background/Purpose: Systemic sclerosis (SSc; scleroderma) is a rare, heterogenous autoimmune disease characterized by skin fibrosis, vasculopathy and internal organ involvement. SSc patients can be divided…Abstract Number: 1068 • 2019 ACR/ARP Annual Meeting
Classical Monocytes from African Ancestry Patients with Systemic Sclerosis Show Transcription and Energy Regulation Gene Expression Signatures
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disorder characterized by immune dysregulation, cutaneous and visceral fibrosis, and vasculopathy. It disproportionately affects African ancestry (AA)…Abstract Number: 1069 • 2019 ACR/ARP Annual Meeting
CD4+ T Helper Cell Populations with High PD-1 Expression Are Expanded in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by tissue fibrosis, vascular injury, and autoantibody production. CXCR5+ PD-1+ T follicular helper (Tfh) cells, which…Abstract Number: 1070 • 2019 ACR/ARP Annual Meeting
Cytokine Signatures Differentiate Systemic Sclerosis Patients at High versus Low Risk for Pulmonary Arterial Hypertension
Background/Purpose: Pulmonary arterial hypertension (PAH) affects approximately 10% of patients with systemic sclerosis (SSc) and is a leading cause of death. Screening algorithms using clinical…Abstract Number: 1071 • 2019 ACR/ARP Annual Meeting
A Common Transcriptional Signature Is Present in Circulating Classical Monocytes and Skin Macrophages in Systemic Sclerosis
Background/Purpose: The etiology and pathogenesis of systemic sclerosis (SSc) are poorly understood; however, an increasing body of evidence supports an early inflammatory phase that precedes…Abstract Number: 1072 • 2019 ACR/ARP Annual Meeting
CCR2+ Circulating Monocytes Contribute to the Survival of ADSC in Bleomycin-Induced Skin Fibrosis
Background/Purpose: Monocytes and monocyte-derived cells play a crucial role during homeostasis and also during the development of various inflammatory diseases including skin fibrosis. Ly6Chi inflammatory…Abstract Number: 1073 • 2019 ACR/ARP Annual Meeting
Identification of Distinct Pro-Fibrotic Monocyte and Macrophage Subsets in Systemic Sclerosis
Background/Purpose: Chronic inflammation may modulate the balance of classical, intermediate and non-classical monocyte subsets (defined by CD14/CD16 expression)1. Monocytes are heterogeneous and subsets can be…
- « Previous Page
- 1
- …
- 827
- 828
- 829
- 830
- 831
- …
- 2425
- Next Page »